Amoéba
Develops natural microbiological solutions to manage bacterial and fungal risks.
ALMIB | PA
Overview
Corporate Details
- ISIN(s):
- FR0011051598 (+2 more)
- LEI:
- 9695005QNE7C8Z0LXU64
- Country:
- France
- Address:
- 38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
- Website:
- https://amoeba-nature.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other chemical products
Description
Amoéba is a biotechnology company that develops natural microbiological solutions for managing bacterial and fungal risks. The company's core technology is based on the patented use of the amoeba *Willaertia magna* C2c Maky and its biocidal properties. Its primary focus is on agricultural biocontrol, offering a biofungicide derived from a mechanically lysed amoeba. This product targets plant diseases such as mildews, rusts, and powdery mildew, providing a biological alternative to chemical treatments. Amoéba has also developed applications for its technology in the treatment of bacterial risk in industrial water systems, on surfaces, and for chronic wounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-20 18:30 |
AXPERA named biocontrol solution of the year 2025 // Amoeba's anti-fungal innov…
|
English | 388.0 KB | ||
| 2025-10-20 18:30 |
AXPERA désignée solution de biocontrôle de l'année 2025 // L'innovation anti-ma…
|
French | 414.4 KB | ||
| 2025-07-22 18:25 |
Amoéba launches a capital increase open to all to support its industrial and co…
|
English | 418.9 KB | ||
| 2025-07-22 17:45 |
Amoéba signs an agreement with Metron Technology, a subsidiary of Oriental Beau…
|
English | 348.1 KB | ||
| 2025-07-22 17:45 |
Amoéba signe un accord avec Metron Technology, filiale du groupe Oriental Beaut…
|
French | 345.8 KB | ||
| 2025-06-17 18:00 |
Amoéba takes another decisive step forward with the final approval of its bioco…
|
English | 391.5 KB | ||
| 2025-06-17 18:00 |
Amoéba franchit une nouvelle étape décisive avec l'approbation définitive de sa…
|
French | 387.4 KB | ||
| 2025-06-03 17:45 |
Koppert et Amoéba signent un accord de distribution majeur pour une solution bi…
|
French | 191.6 KB | ||
| 2025-06-03 17:45 |
Koppert and Amoéba sign major distribution agreement for innovative biofungicid…
|
English | 170.4 KB | ||
| 2025-05-22 18:00 |
Amoéba: Ordinary and Extraordinary General Meeting of 26 June 2025
|
English | 332.5 KB | ||
| 2025-05-22 18:00 |
Amoéba : Assemblée Générale Ordinaire et Extraordinaire du 26 juin 2025
|
French | 331.8 KB | ||
| 2025-05-21 18:00 |
A new milestone towards the market launch of AXPERA: EU Member States unanimous…
|
English | 375.5 KB | ||
| 2025-05-21 18:00 |
Nouvelle étape franchie vers la mise sur le marché d'AXPERA : vote à l'unanimit…
|
French | 372.5 KB | ||
| 2025-05-20 19:00 |
Amoéba announces the nomination of Charlotte Franceries, a leading figure in th…
|
English | 339.5 KB | ||
| 2025-05-20 19:00 |
Amoéba annonce l'arrivée au sein de son Conseil d'administration de Charlotte F…
|
French | 352.3 KB |
Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Amoéba
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Amoéba via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | N/A | Other | Buy | 6,300 | 3,609.90 EUR |
| 2024-08-29 | N/A | Other | Sell | 5,500 | 3,564.00 EUR |
| 2024-08-28 | N/A | Other | Buy | 3,200 | 1,782.08 EUR |
| 2024-08-27 | N/A | Other | Buy | 20,049 | 11,231.45 EUR |
| 2024-08-26 | N/A | Other | Buy | 31,107 | 17,441.69 EUR |
| 2024-08-22 | N/A | Other | Buy | 2,255 | 1,298.88 EUR |
| 2024-08-20 | N/A | Other | Buy | 16,664 | 8,838.59 EUR |
| 2024-08-19 | N/A | Other | Buy | 13,390 | 6,795.43 EUR |
| 2024-08-16 | N/A | Other | Buy | 6,745 | 3,468.28 EUR |
| 2024-08-09 | N/A | Other | Buy | 40,748 | 21,559.77 EUR |
Peer Companies
